Bronchiolitis obliterans may result from lung injury caused by a variety of different chemicals and respiratory infections. Inhaled chemicals known to irritate the lungs and lead to the condition include chlorine; ammonia; oxides of nitrogen or sulfur dioxide; welding fumes; or food flavoring fumes (such as diacetyl). Respiratory infections caused by a respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia have been linked with the condition.
Highlights
The global Bronchiolitis Obliterans Syndrome market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Bronchiolitis Obliterans Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Bronchiolitis Obliterans Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Bronchiolitis Obliterans Syndrome in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Bronchiolitis Obliterans Syndrome include Breath Therapeutics, Genentech, Incyte Corporation, Mereo BioPharma, Altavant Sciences and Koutif Therapeutics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bronchiolitis Obliterans Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bronchiolitis Obliterans Syndrome.
The Bronchiolitis Obliterans Syndrome market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bronchiolitis Obliterans Syndrome market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bronchiolitis Obliterans Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Breath Therapeutics
Genentech
Incyte Corporation
Mereo BioPharma
Altavant Sciences
Koutif Therapeutics
Segment by Type
Inhalation
Oral
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bronchiolitis Obliterans Syndrome companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Bronchiolitis Obliterans Syndrome 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Inhalation
1.2.3 Oral
1.3 麻豆原创 by Application
1.3.1 Global Bronchiolitis Obliterans Syndrome 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bronchiolitis Obliterans Syndrome 麻豆原创 Perspective (2018-2029)
2.2 Bronchiolitis Obliterans Syndrome Growth Trends by Region
2.2.1 Global Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Bronchiolitis Obliterans Syndrome Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Bronchiolitis Obliterans Syndrome Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Bronchiolitis Obliterans Syndrome 麻豆原创 Dynamics
2.3.1 Bronchiolitis Obliterans Syndrome Industry Trends
2.3.2 Bronchiolitis Obliterans Syndrome 麻豆原创 Drivers
2.3.3 Bronchiolitis Obliterans Syndrome 麻豆原创 Challenges
2.3.4 Bronchiolitis Obliterans Syndrome 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bronchiolitis Obliterans Syndrome Players by Revenue
3.1.1 Global Top Bronchiolitis Obliterans Syndrome Players by Revenue (2018-2023)
3.1.2 Global Bronchiolitis Obliterans Syndrome Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Bronchiolitis Obliterans Syndrome 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bronchiolitis Obliterans Syndrome Revenue
3.4 Global Bronchiolitis Obliterans Syndrome 麻豆原创 Concentration Ratio
3.4.1 Global Bronchiolitis Obliterans Syndrome 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bronchiolitis Obliterans Syndrome Revenue in 2022
3.5 Bronchiolitis Obliterans Syndrome Key Players Head office and Area Served
3.6 Key Players Bronchiolitis Obliterans Syndrome Product Solution and Service
3.7 Date of Enter into Bronchiolitis Obliterans Syndrome 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Bronchiolitis Obliterans Syndrome Breakdown Data by Type
4.1 Global Bronchiolitis Obliterans Syndrome Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Bronchiolitis Obliterans Syndrome Forecasted 麻豆原创 Size by Type (2024-2029)
5 Bronchiolitis Obliterans Syndrome Breakdown Data by Application
5.1 Global Bronchiolitis Obliterans Syndrome Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Bronchiolitis Obliterans Syndrome Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Bronchiolitis Obliterans Syndrome 麻豆原创 Size (2018-2029)
6.2 North America Bronchiolitis Obliterans Syndrome 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2018-2023)
6.4 North America Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bronchiolitis Obliterans Syndrome 麻豆原创 Size (2018-2029)
7.2 Europe Bronchiolitis Obliterans Syndrome 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2018-2023)
7.4 Europe Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bronchiolitis Obliterans Syndrome 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Bronchiolitis Obliterans Syndrome 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bronchiolitis Obliterans Syndrome 麻豆原创 Size (2018-2029)
9.2 Latin America Bronchiolitis Obliterans Syndrome 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bronchiolitis Obliterans Syndrome 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Bronchiolitis Obliterans Syndrome 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Bronchiolitis Obliterans Syndrome 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Breath Therapeutics
11.1.1 Breath Therapeutics Company Detail
11.1.2 Breath Therapeutics Business Overview
11.1.3 Breath Therapeutics Bronchiolitis Obliterans Syndrome Introduction
11.1.4 Breath Therapeutics Revenue in Bronchiolitis Obliterans Syndrome Business (2018-2023)
11.1.5 Breath Therapeutics Recent Development
11.2 Genentech
11.2.1 Genentech Company Detail
11.2.2 Genentech Business Overview
11.2.3 Genentech Bronchiolitis Obliterans Syndrome Introduction
11.2.4 Genentech Revenue in Bronchiolitis Obliterans Syndrome Business (2018-2023)
11.2.5 Genentech Recent Development
11.3 Incyte Corporation
11.3.1 Incyte Corporation Company Detail
11.3.2 Incyte Corporation Business Overview
11.3.3 Incyte Corporation Bronchiolitis Obliterans Syndrome Introduction
11.3.4 Incyte Corporation Revenue in Bronchiolitis Obliterans Syndrome Business (2018-2023)
11.3.5 Incyte Corporation Recent Development
11.4 Mereo BioPharma
11.4.1 Mereo BioPharma Company Detail
11.4.2 Mereo BioPharma Business Overview
11.4.3 Mereo BioPharma Bronchiolitis Obliterans Syndrome Introduction
11.4.4 Mereo BioPharma Revenue in Bronchiolitis Obliterans Syndrome Business (2018-2023)
11.4.5 Mereo BioPharma Recent Development
11.5 Altavant Sciences
11.5.1 Altavant Sciences Company Detail
11.5.2 Altavant Sciences Business Overview
11.5.3 Altavant Sciences Bronchiolitis Obliterans Syndrome Introduction
11.5.4 Altavant Sciences Revenue in Bronchiolitis Obliterans Syndrome Business (2018-2023)
11.5.5 Altavant Sciences Recent Development
11.6 Koutif Therapeutics
11.6.1 Koutif Therapeutics Company Detail
11.6.2 Koutif Therapeutics Business Overview
11.6.3 Koutif Therapeutics Bronchiolitis Obliterans Syndrome Introduction
11.6.4 Koutif Therapeutics Revenue in Bronchiolitis Obliterans Syndrome Business (2018-2023)
11.6.5 Koutif Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Breath Therapeutics
Genentech
Incyte Corporation
Mereo BioPharma
Altavant Sciences
Koutif Therapeutics
听
听
*If Applicable.
